BridgeBio Pharma, Inc. 2CL.F Stock
BridgeBio Pharma, Inc. Price Chart
BridgeBio Pharma, Inc. 2CL.F Financial and Trading Overview
BridgeBio Pharma, Inc. stock price | 25.82 EUR |
Previous Close | 15.4 EUR |
Open | 13.99 EUR |
Bid | 13.99 EUR x N/A |
Ask | 14.37 EUR x N/A |
Day's Range | 13.99 - 13.99 EUR |
52 Week Range | 6.09 - 17.84 EUR |
Volume | 125 EUR |
Avg. Volume | 47 EUR |
Market Cap | 2.29B EUR |
Beta (5Y Monthly) | 0.706023 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.68 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 80.4 EUR |
2CL.F Valuation Measures
Enterprise Value | 3.72B EUR |
Trailing P/E | N/A |
Forward P/E | -3.9078212 |
PEG Ratio (5 yr expected) | 0.19 |
Price/Sales (ttm) | 29.480984 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 47.844 |
Enterprise Value/EBITDA | -8.581 |
Trading Information
BridgeBio Pharma, Inc. Stock Price History
Beta (5Y Monthly) | 0.706023 |
52-Week Change | 151.76% |
S&P500 52-Week Change | 20.43% |
52 Week High | 17.84 EUR |
52 Week Low | 6.09 EUR |
50-Day Moving Average | 13.59 EUR |
200-Day Moving Average | 10.89 EUR |
2CL.F Share Statistics
Avg. Volume (3 month) | 47 EUR |
Avg. Daily Volume (10-Days) | 5 EUR |
Shares Outstanding | 160.5M |
Float | 93.11M |
Short Ratio | N/A |
% Held by Insiders | 5.74% |
% Held by Institutions | 90.98% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -565.97% |
Gross Margin | 96.48% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -38.24% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 77.78M EUR |
Revenue Per Share (ttm) | 0.52 EUR |
Quarterly Revenue Growth (yoy) | 7.79% |
Gross Profit (ttm) | 74.21M EUR |
EBITDA | -433695008 EUR |
Net Income Avi to Common (ttm) | -424942016 EUR |
Diluted EPS (ttm) | -2.65 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 491.29M EUR |
Total Cash Per Share (mrq) | 3.06 EUR |
Total Debt (mrq) | 1.73B EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 5.722 |
Book Value Per Share (mrq) | -7.64 |
Cash Flow Statement
Operating Cash Flow (ttm) | -403180992 EUR |
Levered Free Cash Flow (ttm) | -253781744 EUR |
Profile of BridgeBio Pharma, Inc.
Country | Germany |
State | CA |
City | Palo Alto |
Address | 3160 Porter Drive |
ZIP | 94304 |
Phone | 650 391 9740 |
Website | https://www.bridgebio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 392 |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Q&A For BridgeBio Pharma, Inc. Stock
What is a current 2CL.F stock price?
BridgeBio Pharma, Inc. 2CL.F stock price today per share is 25.82 EUR.
How to purchase BridgeBio Pharma, Inc. stock?
You can buy 2CL.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BridgeBio Pharma, Inc.?
The stock symbol or ticker of BridgeBio Pharma, Inc. is 2CL.F.
Which industry does the BridgeBio Pharma, Inc. company belong to?
The BridgeBio Pharma, Inc. industry is Biotechnology.
How many shares does BridgeBio Pharma, Inc. have in circulation?
The max supply of BridgeBio Pharma, Inc. shares is 184.45M.
What is BridgeBio Pharma, Inc. Price to Earnings Ratio (PE Ratio)?
BridgeBio Pharma, Inc. PE Ratio is now.
What was BridgeBio Pharma, Inc. earnings per share over the trailing 12 months (TTM)?
BridgeBio Pharma, Inc. EPS is -3.68 EUR over the trailing 12 months.
Which sector does the BridgeBio Pharma, Inc. company belong to?
The BridgeBio Pharma, Inc. sector is Healthcare.